Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment
Published: 8 Dec 2020
Views: 109
Prof Monica Bocchia - University of Siena, Siena, Italy
Prof Monica Bocchia speaks to ecancer in an online interview for the virtual ASH 2020 meeting about the interim results of the PROSPECTIVE FLOWERS study.
The multicentre prospective study looked at peripheral blood CD26 leukaemia stem cell monitoring in chronic myeloid leukaemia patients during TKI treatment.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.
Related Videos
Latest in non-small cell lung cancer pathology
Prof Benjamin Besse and Prof Albrecht Stenzinger
6 Jan 2021
The Burkitt lymphoma international prognostic index
Prof Adam Olszewski - Brown University, Providence, USA
24 Dec 2020
Researchers trace the origin of blood cancer to early childhood, decades before ...
Dr Jyoti Nangalia - University of Cambridge, Cambridge, UK
16 Dec 2020
Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by ...
Dr Alex Herrera - City of Hope Comprehensive Cancer Center, Duarte, USA
15 Dec 2020
ASCENT: A phase II trial of induction, consolidation and maintenance in subjects...
Prof Andrzej Jakubowiak - University of Chicago, Chicago, USA
9 Dec 2020
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combina...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
8 Dec 2020
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin l...
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
8 Dec 2020
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-ye...
Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
7 Dec 2020
Prophylactic gastrectomy in CDH1 mutation
Prof. Franco Roviello - University of Siena, Italy
22 Jul 2020
